Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Inhaled Granulocyte-Macrophage Colony-Stimulating factor

6 evidence topics · 11 sources

ERS recommendation for symptomatic autoimmune PAP

“We recommend inhaled GM-CSF for symptomatic patients with confirmed autoimmune PAP.” (opens the source at this quote in a new tab)
“(Strong recommendation, very low certainty of evidence.)” (opens the source at this quote in a new tab)

Meta-analysis: DLCO percent predicted

“Inhaled GM-CSF significantly enhanced DLCO% predicted (MD 5.09; 95% CI 2.05 to 8.13; p = 0.001; I² = 0%)” (opens the source at this quote in a new tab)

Nebulized GM-CSF systematic review: serious adverse events

“No serious trial-related adverse events were reported.” (opens the source at this quote in a new tab)

Sargramostim after whole lung lavage

“This long-term, prospective, randomised trial demonstrated inhaled sargramostim following WLL reduced the requirement for WLL, improved lung function and was safe in aPAP patients.” (opens the source at this quote in a new tab)

Mild-to-moderate disease trial: primary endpoint

“We found no significant response in the primary endpoint” (opens the source at this quote in a new tab)

Long-term inhaled GM-CSF: relapse during dose de-escalation

“Two patients relapsed at de-escalating doses.” (opens the source at this quote in a new tab)